Does the Use of Low Molecular Weight Heparin Affect Pregnancy Screening Test Results?


Abstract views: 101 / PDF downloads: 37

Authors

  • Ali GÜRSOY Maltepe University

DOI:

https://doi.org/10.5281/zenodo.7603988

Keywords:

First Pregnancy Trimester, Low Molecular Weight Heparin, Maternal Serum Screening Tests, Neural Tube Defects

Abstract

Objective: Low molecular weight heparin, also known as LMWH, is a drug that is frequently utilized in the treatment of venous thromboembolism risk management as well as the prevention of potential miscarriages in pregnancy. Our study sought to answer the question of whether or not the use of LMWH, which is becoming increasingly popular as a treatment option in clinical settings, has an impact on the outcomes of screening tests administered during the first trimester of pregnancy as well as tests intended to detect birth defects in the neural tube.

Methods: This retrospective case-control study included pregnant women who had a first trimester screening test and a neural tube defect screening test during pregnancy follow-up. A comparison was made between fifty-three pregnant women using LMWH and three hundred twenty-five pregnant women not using LMWH. Serum beta human chorionic gonadotropin (beta-hCG), placenta associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP) levels were investigated in this study.

Results: Patients included in the study ranged in age from 20 to 47 years. In terms of first trimester screening test markers PAPP-A, PAPP-A multiples of the media (MoM), beta-hCG, beta-hCG MoM, and neural tube defect markers AFP, AFP MoM (p> 0.05), there was no significant difference between the control group and LMWH group (p> 0.05).

Conclusion: Our study has shown that the use of LMWH during pregnancy does not cause misinterpretation of first trimester screening test and neural tube defect screening tests. Further studies with larger samples are required to confirm our findings.

References

Akhtar MA, Sur S, Raine-Fenning N, Jayaprakasan K, Thornton JG, Quenby S. Heparin for assisted reproduction. Cochrane Database Syst Rev. 2013 Aug 17;(8):CD009452. doi: 10.1002/14651858.CD009452.pub2. PMID: 23955506.

Aracic N, Roje D, Jakus IA, Bakotin M, Stefanovic V. The Impact of Inherited Thrombophilia Types and Low Molecular Weight Heparin Treatment on Pregnancy Complications in Women with Previous Adverse Outcome. Yonsei Med J. 2016 Sep;57(5):1230-5. doi: 10.3349/ymj.2016.57.5.1230. PMID: 27401656; PMCID: PMC4960391.

Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987 Nov;7(9):623-30. doi: 10.1002/pd.1970070904. PMID: 2447576.

Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003 Jun;16(2):153-68. doi: 10.1016/s1521-6926(03)00021-5. PMID: 12763484.

Flores-Alatriste JD, Jacobo-Nájera S, Segura-Rodríguez R, Stern-Colin y Nunes JJ. Pacientes con trombofilias hereditarias y pérdida gestacional recurrente: incidencia [Patients with inherited trombophilia and recurrent pregnancy loss: incidence]. Ginecol Obstet Mex. 2014 Jun;82(6):383-8. Spanish. PMID: 25016897.

Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005 Jul 15;106(2):401-7. doi: 10.1182/blood-2005-02-0626. Epub 2005 Apr 5. PMID: 15811953.

Heinig J, Steinhard J, Schmitz R, Nofer JR, Kiesel L, Klockenbusch W. Influence of maternal systemic lupus erythematosus on first-trimester combined screening for chromosomal abnormalities. Prenat Diagn. 2007 Jul;27(7):600-2. doi: 10.1002/pd.1737. PMID: 17437322.

Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005 Nov 15;143(10):697-706. doi: 10.7326/0003-4819-143-10-200511150-00006. PMID: 16287790.

Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol. 2008 Feb;198(2):233.e1-7. doi: 10.1016/j.ajog.2007.08.041. Epub 2007 Nov 12. PMID: 17997389.

Jacobson B, Rambiritch V, Paek D, Sayre T, Naidoo P, Shan J, Leisegang R. Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. Adv Ther. 2020 Jan;37(1):27-40. doi: 10.1007/s12325-019-01124-z. Epub 2019 Oct 31. PMID: 31673991; PMCID: PMC6979442.

James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006 May;194(5):1311-5. doi: 10.1016/j.ajog.2005.11.008. Epub 2006 Apr 21. PMID: 16647915.

Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008 Jun;31(6):618-24. doi: 10.1002/uog.5331. PMID: 18461550.

Middeldorp S. Pregnancy failure and heritable thrombophilia. Semin Hematol. 2007 Apr;44(2):93-7. doi: 10.1053/j.seminhematol.2007.01.005. PMID: 17433901.

Mizejewski GJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med (Maywood). 2004 Jun;229(6):439-63. doi: 10.1177/153537020422900602. PMID: 15169963.

Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol. 2005 Aug;29(4):190-4. doi: 10.1053/j.semperi.2005.06.001. PMID: 16104667.

Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004 Jul;191(1):45-67. doi: 10.1016/j.ajog.2004.03.090. PMID: 15295343.

Nwabuobi C, Arlier S, Schatz F, Guzeloglu-Kayisli O, Lockwood CJ, Kayisli UA. hCG: Biological Functions and Clinical Applications. Int J Mol Sci. 2017 Sep 22;18(10):2037. doi: 10.3390/ijms18102037. PMID: 28937611; PMCID: PMC5666719.

Palomaki GE, Bupp C, Gregg AR, Norton ME, Oglesbee D, Best RG; ACMG Biochemical Genetics Subcommittee of the Laboratory Quality Assurance Committee. Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020 Mar;22(3):462-474. doi: 10.1038/s41436-019-0681-0. Epub 2019 Nov 8. PMID: 31700163.

Papadakis E, Pouliakis A, Aktypi Α, Christoforidou A, Kotsi P, Αnagnostou G, … Grouzi E. Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature. Thromb J. 2019 Dec 4;17:23. doi: 10.1186/s12959-019-0213-9. PMID: 31827408; PMCID: PMC6894228.

Peeva G, Oakley L, von Rège I, Nicolaides K, Oteng-Ntim E. Does first-trimester serum pregnancy-associated plasma protein A differ in pregnant women with sickle cell disease? Prenat Diagn. 2019 Sep;39(10):921-924. doi: 10.1002/pd.5507. Epub 2019 Jul 28. PMID: 31240733.

Petri M, Ho AC, Patel J, Demers D, Joseph JM, Goldman D. Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. J Rheumatol. 1995 Jul;22(7):1365-8. PMID: 7562773

Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, … Hod M. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019 May;145 Suppl 1(Suppl 1):1-33. doi: 10.1002/ijgo.12802. Erratum in: Int J Gynaecol Obstet. 2019 Sep;146(3):390-391. PMID: 31111484; PMCID: PMC6944283.

Rai R, Regan L. Recurrent miscarriage. Lancet. 2006 Aug 12;368(9535):601-11. doi: 10.1016/S0140-6736(06)69204-0. PMID: 16905025.

RCOG. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. RCOG Green-top Guideline No. 37a. London: Royal College of Obstetricians and Gynaecologists; 2015. p. 1–40. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf.

Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome. Indian J Clin Biochem. 2013 Jan;28(1):3-12. doi: 10.1007/s12291-012-0269-9. Epub 2012 Oct 12. PMID: 24381414; PMCID: PMC3547446.

Tan JY. Thrombophilia in pregnancy. Ann Acad Med Singap. 2002 May;31(3):328-34. PMID: 12061293.

Turkcapar F, Engin-Üstün Y, Simsek OY, Deveer R, Danisman N, Dilmen U, Mollamahmutoglu L. First and second trimester biochemical markers in familial mediterranean fever. Eur Rev Med Pharmacol Sci. 2013 Jul;17(13):1820-3. PMID: 23852910.

Unal C, Tanacan A, Fadiloglu E, Portakal O, Beksac MS. Effect of anti-epileptic drugs on first trimester screening test results. Taiwan J Obstet Gynecol. 2020 Nov;59(6):835-837. doi: 10.1016/j.tjog.2020.09.009. PMID: 33218397.

Wilson RD; SOGC Genetıcs Commıttee; Specıal Contrıbutor. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can. 2014 Oct;36(10):927-939. doi: 10.1016/S1701-2163(15)30444-8. PMID: 25375307.

Downloads

Published

2023-02-04

How to Cite

GÜRSOY, A. (2023). Does the Use of Low Molecular Weight Heparin Affect Pregnancy Screening Test Results? . GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES, 8(1), 91–96. https://doi.org/10.5281/zenodo.7603988

Issue

Section

Articles